Family Chiropractic of Chattanooga

01/28/2026

01/27/2026

Our office IS OPEN today, Tuesday 27th!

01/14/2026

Tylenol, a common over-the-counter medication, is often seen as a safe solution for relieving pain and reducing fever in children. However, recent studies have raised concerns about its long-term effects. Research shows that taking Tylenol even once a year can significantly increase a child's risk of developing asthma, with some studies indicating a 50% higher risk. Additionally, Tylenol use has been linked to an increased likelihood of allergic rhinitis and eczema, conditions that can significantly impact a child’s quality of life.

What’s more alarming is the strain Tylenol places on the liver. It’s known to be the number one cause of liver failure in children, leading to thousands of emergency room visits each year. Despite being marketed as safe, the risks associated with Tylenol usage cannot be ignored. Parents should be more cautious about using this medication and consider other alternatives whenever possible, such as natural remedies or preventative health practices.

This issue has sparked an important conversation about the reliance on pharmaceutical drugs for treating common childhood illnesses. Instead of reaching for Tylenol at the first sign of discomfort, it may be better to explore natural methods of pain management and fever reduction, focusing on holistic approaches to health. ⚠️🧒

01/13/2026

🚨 A thought-provoking analysis highlights a lesser-discussed limitation of the DTaP (acellular pertussis) vaccine, introduced in the 1990s to replace the whole-cell version due to fewer side effects.

Pertussis expert Dr. James D. Cherry, in his 2019 review "The 112-Year Odyssey of Pertussis and Pertussis Vaccines," notes that the acellular vaccine's limited antigens (3–5 vs. >3,000 in whole-cell) may trigger linked-epitope suppression, a form of original antigenic sin, leading to blunted immune responses to natural infection.

He states: "Because of linked-epitope suppression, all children who were primed by DTaP vaccines will be more susceptible to pertussis throughout their lifetimes, and there is no easy way to decrease this increased lifetime susceptibility."

Additionally, historical data show whooping cough mortality in England and Wales declined over 97% from 1901–1945, largely due to improvements in sanitation, nutrition, and living conditions—before widespread vaccination.

This raises important questions about vaccine design trade-offs, waning immunity, and the ongoing pertussis resurgence despite high coverage.

🔗 Worth reading for a deeper understanding: https://romanbystrianyk.substack.com/p/the-vaccine-mistake-nobody-talks

12/29/2025

New research has revealed a startling fact: children’s skulls are about 50% thinner than adult skulls, allowing up to 80% of radiation from mobile phones to pe*****te directly to the developing brain. This discovery raises concerns about the potential long-term effects of prolonged exposure to electromagnetic fields on growing neural tissue.

Scientists used advanced imaging techniques and computer simulations to measure skull thickness and model how radiation travels through bone. Their findings indicate that thinner bone structure, combined with smaller head size, makes children significantly more vulnerable to radiofrequency energy than adults. The study highlights the importance of understanding how everyday technology interacts with the developing brain, which is still forming critical neural pathways, synapses, and cognitive functions.

While researchers caution that more studies are needed to fully assess health risks, they emphasize the need for protective measures. Recommendations include limiting prolonged phone calls, using speaker mode or headphones, and encouraging safer habits for children who use mobile devices frequently. This is particularly urgent as children increasingly rely on smartphones for education, communication, and entertainment.

The findings serve as a wake-up call for parents, educators, and policymakers to prioritize safe technology use for younger populations. Scientists hope these insights will drive further research into minimizing exposure and safeguarding brain health while still benefiting from modern communication tools.

12/26/2025

12/24/2025

12/13/2025

🚨 FDA Opens Formal Safety Investigation into RSV Monoclonal Antibodies for Infants Following Concerning Mortality Signals in Clinical Trials

The products under review are Beyfortus (AstraZeneca/Sanofi) and the newly approved Enflonsia (Merck).

These are not traditional vaccines but long-acting monoclonal antibodies administered to nearly all U.S. infants—often within hours of birth—to prevent severe RSV.

Here’s what the FDA is now forced to scrutinize:

• Beyfortus Phase 3 trials (MELODY + HARMONIE pooled): 5 infant deaths in the nirsevimab group vs. ZERO in placebo

• Enflonsia trials: additional imbalances (5–1 and 7–3 across studies)

• Breakthrough RSV cases in treated infants required longer hospital stays than placebo cases—raising the terrifying specter of antibody-dependent enhancement (the same mechanism that killed toddlers in the infamous 1960s RSV vaccine disaster)

• Post-marketing reports: CDC emails document at least two infants who died within hours of receiving Beyfortus

• French pharmacovigilance data: statistically improbable spike in neonatal deaths temporally linked to the shot

• ACIP member Dr. Robert Malone (yes, that Dr. Malone) now says he regrets voting to approve Enflonsia, citing manipulated trial endpoints and hidden safety signals

The manufacturers keep repeating “deaths unrelated” and “not statistically significant,” but when the scorecard is literally 5–0, 5–1, and 7–3 in favor of dead babies in the treatment arms, “not statistically significant” starts sounding like corporate damage control.

Beyfortus alone generated $2.6 BILLION in its first year—Merck is already projecting $250M+ for Enflonsia in 2026.

Follow the money. 💰

This is the biggest infant pharmaceutical rollout since rotavirus, and the FDA is finally admitting the mortality imbalance can’t be waved away.

Parents: your pediatrician will almost certainly push one of these at the next visit. You now have documented, FDA-acknowledged reasons to hit pause and demand answers.